Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pepticom oral IL-17 peptide inhibitor
- Development stage
- Preclinical
- Lead developer
- Pepticom
- Modality
- Peptides
- Administration
- Oral
01
Overview
Pepticom is developing an AI-designed, orally administered peptide therapeutic targeting the IL-17 pathway for the treatment of plaque psoriasis. The program utilizes fully synthetic, small cyclic peptidomimetic inhibitors that target both IL-17A and IL-17F isoforms with nanomolar activity. These compounds are engineered for high stability and extended half-life using non-natural amino acids. By inhibiting IL-17-mediated inflammation, this drug aims to provide an oral alternative to existing injectable IL-17 blockers. The program is currently in the lead optimization phase, with a formal drug candidate expected to be announced in 2025.
- Other names
- Pepticom-IL-17-Peptide-oral-Plaque PsoriasisPepticom-IL17-Peptide-oral-Plaque PsoriasisPepticom-IL 17-Peptide-oral-Plaque PsoriasisPepticom oral IL-17 peptideAI-designed oral IL-17 peptide
02
Targets
IL17F (Interleukin 17F)IL-17A (Interleukin-17A)
Beyond the preview
Go deeper on Pepticom oral IL-17 peptide inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pepticom oral IL-17 peptide inhibitor.